Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Novel Approach Simplifies Complex Sugars on Protein-Based Biotech Medicines

By BiotechDaily International staff writers
Posted on 25 May 2014
A team of biotech medicine developers has established a cell-based production method that reduces the complexity of the sugars (glycans) expressed on protein-based drugs.

Heterogeneity in the N-glycans on therapeutic proteins causes difficulties for protein purification and process reproducibility and can lead to variable therapeutic efficacy. This heterogeneity arises from the multistep process of mammalian complex-type N-glycan synthesis.

Investigators at, Ghent University (Belgium) recently described a novel glycoengineering strategy that they called GlycoDelete, which used a fungal enzyme to shorten the Golgi N-glycosylation pathway in mammalian cells.

They wrote in the April 20, 2014, online edition of the journal Nature Biotechnology that this shortening resulted in the expression of proteins with small, sialylated trisaccharide N-glycans and reduced complexity compared to native mammalian cell glycoproteins. GlycoDelete engineering did not interfere with the functioning of N-glycans in protein folding, and the physiology of cells modified by GlycoDelete was similar to that of wild-type cells. This strategy for reducing N-glycan heterogeneity on mammalian proteins could lead to more consistent performance of therapeutic proteins and modulation of biopharmaceutical functions.

Senior author Dr. Nico Callewaert, professor of medical biotechnology at Ghent University, said, “This technology has allowed us to solve an old biotech problem. Since the 1990s, nearly everyone has been working to make the sugar synthesis in biotech production cells as similar to human cells as possible. This is a very difficult task, because there are so many steps in this synthesis pathway. We have been able to create a detour in this synthesis pathway in a fairly simple manner, making the pathway much shorter and simpler.”

Related Links:

Ghent University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.